RESUMO
Around 2 million people are diagnosed with lung cancer annually, causing 20,000 deaths. Non-small cell carcinomas account for 80-85% of lung cancer cases. Over the last few decades, there has been an improved understanding of the chromosomal makeup of lung cancer. As a result, the clinical care and treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) have changed. This is possible due to advanced molecular techniques and chromosomal analysis, which have revealed persistent genetic abnormalities. Specific medications have increased the median survival time for NSCLC patients. Pulmonary pathology and oncology patients now receive personalized medication based on genetic abnormalities and other prognostic indicators. However, the diagnosis algorithms become complicated due to the various testing methods available. Consensus standards and recommendations have standardized NSCLC diagnostic testing. This article discusses the molecular genetic landscape of NSCLC and the latest therapy developments, focusing on clinically relevant changes using several schematic and tabular representations.
